Josh Bilenker, Loxo
Loxo chief Josh Bilenker steps in (temporarily) to head oncology R&D at Eli Lilly as Levi Garraway steps out
Josh Bilenker didn’t just gain a personal windfall by selling Loxo to Eli Lilly for $8.1 billion. He got a new, if temporary, job out of the deal as well.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
